Twist Bioscience Securities Class Action Settlement ($17.05M)

Current Status

Claims are open. A Proof of Claim must be submitted online, or postmarked if mailed, no later than November 17, 2026; the notice states the date without a timezone, so treat the date itself as the cutoff. The court has conditionally certified a settlement class and authorized notice, and the deadline to exclude yourself or to object is October 7, 2026. A final approval hearing is scheduled for November 18, 2026 at 10:00 a.m. before the U.S. District Court for the Northern District of California in San Jose — one day after the claim deadline. No final approval order has been entered, and no payment date has been announced. Payments follow only after the court approves the settlement and the plan of allocation, after any appeals are resolved, and after every claim has been processed.

What Is the Case About?

Twist Bioscience makes synthetic DNA on a silicon-based platform and sells it to diagnostics companies, hospitals, drug developers and academic labs. Its stock trades on the Nasdaq under the ticker TWST. Through the period covered by this case the company told investors its chip-based writing technology produced DNA at far higher volume and far lower cost than conventional methods, reported rising gross margins, and described a new Oregon manufacturing plant it called a factory of the future.

The lawsuit alleges that statements about Twist's production process, product quality and accounting were materially false or misleading. According to the complaint, the allegedly corrective information reached the market on November 15, 2022, when a short-seller published a report questioning the technology, the company's margins and how it classified certain manufacturing costs. Twist's stock closed at $30.43 that day, down $7.57, or roughly 20%, from $38.00 the day before. The claims are brought under Sections 11 and 15 of the Securities Act of 1933, which target misstatements in offering documents, and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

The defendants — Twist Bioscience Corporation and two of its officers — deny all of it. They deny making any materially false or misleading statement or actionable omission, deny any act or omission giving rise to liability, and deny that the class suffered any loss attributable to their conduct. The settlement is expressly not an admission of wrongdoing, and no court has found any of the allegations true. In September 2025 the court granted in part and denied in part the defendants' motion to dismiss, allowing certain claims to proceed against certain defendants; that ruling decided which allegations could be litigated, not whether they were correct.

Who Qualifies?

The conditionally certified settlement class is all persons who purchased or otherwise acquired Twist common stock in the December 2020 offering pursuant to the 2020 registration statement and were damaged, and/or between December 20, 2018 and November 15, 2022, both dates inclusive, and were damaged.

The December 2020 offering is a specific event: Twist completed a secondary offering on December 2, 2020 in which it sold 3,136,362 shares at $110.00 per share, including 409,090 shares sold when the underwriters exercised their option in full. Shares bought in that offering are eligible under both the Securities Act and the Exchange Act calculations described below; shares bought on the open market during the class period run through the Exchange Act calculation only.

Excluded from the class are the defendants and their affiliates and subsidiaries; Twist's present and former officers and directors and their immediate family members; the defendants' liability insurance carriers and their affiliates; any entity in which a defendant had a controlling interest; Twist's employee retirement and benefit plans; and the legal representatives, heirs, estates, agents, successors and assigns of anyone in those categories. Anyone who validly excludes themselves by October 7, 2026 is also out.